M
Muskler, led og knogler
Interleukin-17-hæmmere (biologiske antireumatika)
L04AC
Interleukin-17 cytokinerne er proinflammatoriske. Familien består af IL-17 A, B, C, D, E og F. IL-17A og F produceres bl.a. af Th17 lymfocytter og spiller en vigtig rolle i den autoimmune inflammation ved psoriasis, psoriasis artrit og spondylartrit.
Præparater
| Indholdsstof | Navn og firma | Dispform og styrke | Pakning | Pris enh. | Pris DDD |
|---|---|---|---|---|---|
| Secukinumab | Cosentyx Novartis
|
injektionsvæske, opl. i pen 150 mg | 2 stk. | 5.174,53 | 344,97 |
| Secukinumab | Cosentyx Novartis
|
injektionsvæske, opl. i pen 300 mg | 1 stk. | 10.349,05 | 344,97 |
| Secukinumab | Cosentyx Novartis
|
injektionsvæske, opl. i sprøjte 75 mg | 1 stk. | 2.599,90 | 346,65 |
Referencer
5177. Blair HA. Secukinumab: A Review in Ankylosing Spondylitis. Drugs. 2019; 79:433-43, https://pubmed.ncbi.nlm.nih.gov/30793255/ (Lokaliseret 4. marts 2022)
3095. Baeten D, Sieper J, Braun J et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.. N Engl J Med. 2015; 373(26):2534-48, https://www.ncbi.nlm.nih.gov/pubmed/26699169 (Lokaliseret 18. februar 2022)
3096. McInnes IB, Mease PJ, Kirkham B et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; :1137-46, https://www.ncbi.nlm.nih.gov/pubmed/26135703 (Lokaliseret 18. februar 2022)
3097. McInnes IB, Sieper J, Braun J. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014; 73(2):349-56, https://www.ncbi.nlm.nih.gov/pubmed/23361084 (Lokaliseret 18. februar 2022)
